Showing 20 of 80 recruiting trials for “Multiple myeloma”
Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant
👨⚕️ Dilan A Patel, M.D., Washington University School of Medicine📍 1 site📅 Started Apr 2025View details ↗
Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
RecruitingNCT06644625 ↗
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
👨⚕️ Manisha Bhutani, MD, Atrium Health Wake Forest Baptist Comprehensive Cancer Center📍 1 site📅 Started Mar 2025View details ↗
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
👨⚕️ Barry A Paul, MD, Wake Forest University Health Sciences📍 2 sites📅 Started Feb 2025View details ↗
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
👨⚕️ David Avigan, MD, Beth Israel Deaconess Medical Center📍 2 sites📅 Started Jan 2025View details ↗
RecruitingNCT06846905 ↗
Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
👨⚕️ Ricardo D Parrondo, Dana-Farber - Harvard Cancer Center LAO📍 14 sites📅 Started Dec 2024View details ↗
VitD3 Supplementation in Patients With Multiple Myeloma
👨⚕️ Amany Keruakous, MD, Georgia Cancer Center at Augusta University📍 1 site📅 Started Dec 2024View details ↗
Risk Stratification and MRD-driven Maintenance for MM After ASCT
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
👨⚕️ Armin Ghobadi, M.D., Washington University School of Medicine📍 1 site📅 Started Aug 2024View details ↗
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
👨⚕️ Ying Lu, The Affiliated People's Hospital of Ningbo University📍 16 sites📅 Started Aug 2024View details ↗
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
RecruitingNCT06338150 ↗
Precision Medicine Study
👨⚕️ Cesar Rodriguez Valdes, MD, PhD, Icahn School of Medicine at Mount Sinai📍 1 site📅 Started Jul 2024View details ↗
PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)
Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
RecruitingNCT05530096 ↗
Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD
👨⚕️ Rayan Kaedbey, Sir Mortimer B. Davis - Jewish General Hospital📍 1 site📅 Started May 2024View details ↗
Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM
🏥 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology📍 1 site📅 Started Apr 2024View details ↗
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →